Castle Creek Biosciences is developing gene therapies to treat severe rare diseases, including DEB and hereditary metabolic conditions. Its lead candidate, D-Fi™, has demonstrated clinical success in a phase III trial for DEB, with a BLA submission expected later this year. Castle Creek has also expanded its pipeline via the acquisition of Novavita Thera and is now advancing LV-FAH, an in vivo gene therapy for hereditary tyrosinemia type 1, into phase II.